Shattuck Labs (NASDAQ:STTK) Receives Neutral Rating from HC Wainwright

Shattuck Labs (NASDAQ:STTK)‘s stock had its “neutral” rating restated by equities researchers at HC Wainwright in a research report issued to clients and investors on Thursday,Benzinga reports.

STTK has been the subject of a number of other reports. Leerink Partners began coverage on Shattuck Labs in a research report on Monday, March 17th. They issued an “outperform” rating and a $4.00 price objective for the company. Leerink Partnrs raised shares of Shattuck Labs to a “strong-buy” rating in a research note on Monday, March 17th. Four research analysts have rated the stock with a hold rating, one has given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $7.50.

Shattuck Labs Stock Performance

Shares of NASDAQ STTK traded down $0.11 during trading on Thursday, reaching $1.07. The company had a trading volume of 59,714 shares, compared to its average volume of 376,809. Shattuck Labs has a 52 week low of $0.94 and a 52 week high of $11.76. The business’s 50 day moving average price is $1.24 and its 200-day moving average price is $1.51. The stock has a market cap of $50.89 million, a PE ratio of -0.70 and a beta of 1.66.

Institutional Investors Weigh In On Shattuck Labs

Large investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. raised its holdings in Shattuck Labs by 63.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 27,533 shares of the company’s stock valued at $96,000 after acquiring an additional 10,667 shares during the period. Geode Capital Management LLC grew its position in shares of Shattuck Labs by 0.9% in the third quarter. Geode Capital Management LLC now owns 912,202 shares of the company’s stock valued at $3,184,000 after purchasing an additional 8,133 shares during the last quarter. MetLife Investment Management LLC increased its stake in shares of Shattuck Labs by 129.1% during the third quarter. MetLife Investment Management LLC now owns 24,596 shares of the company’s stock worth $86,000 after purchasing an additional 13,859 shares during the period. State Street Corp lifted its holdings in Shattuck Labs by 7.8% during the 3rd quarter. State Street Corp now owns 766,410 shares of the company’s stock worth $2,675,000 after purchasing an additional 55,579 shares during the last quarter. Finally, Barclays PLC boosted its stake in Shattuck Labs by 299.5% in the 3rd quarter. Barclays PLC now owns 54,311 shares of the company’s stock valued at $189,000 after purchasing an additional 40,717 shares during the period. Institutional investors own 58.74% of the company’s stock.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.